| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
This compound is a metabolite, not a drug; D-fructose-6-phosphate is a substrate for phosphofructokinase and other glycolytic enzymes in cellular energy metabolism.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers for quantification throughout the drug development process. Due to its potential to alter the pharmacokinetic and metabolic characteristics of medications, deuteration has drawn attention[1].
The labeled compound has the same biochemical activity as unlabeled D-fructose-6-phosphate; it is phosphorylated by PFK to generate fructose-1,6-bisphosphate and serves as a carbon source in glycolysis. |
| ln Vivo |
In vivo, the labeled compound is metabolized identically to endogenous fructose-6-phosphate; it is incorporated into glycolytic and gluconeogenic pathways and traced by mass spectrometry in metabolic flux experiments.
|
| Enzyme Assay |
Enzyme activity assays (e.g., PFK assay) are performed by incubating the enzyme with fructose-6-phosphate and ATP; product formation is coupled to NADH oxidation and monitored spectrophotometrically at 340 nm.
|
| Cell Assay |
Cells are cultured in medium containing 13C6-labeled fructose-6-phosphate; metabolites are extracted with cold organic solvents and analyzed by LC-MS to track 13C incorporation into downstream metabolites such as DHAP, G3P, and pyruvate.
|
| Animal Protocol |
Mice or rats are administered the labeled compound via intravenous or intraperitoneal injection; blood is collected at timed intervals, plasma is deproteinized, and 13C enrichment in glucose and lactate is measured by GC-MS or LC-MS.
|
| ADME/Pharmacokinetics |
The labeled compound is metabolized identically to the unlabeled form; fructose-6-phosphate is rapidly taken up by cells and enters glycolysis, with a plasma half-life of minutes to hours depending on species.
|
| Toxicity/Toxicokinetics |
No toxicity studies are available for the labeled compound; unlabeled fructose-6-phosphate is an endogenous metabolite with minimal toxicity; the labeled analog is safe for research use at typical tracer doses.
|
| References | |
| Additional Infomation |
This product is a stable isotope-labeled analytical standard for metabolic research; it is not a pharmaceutical drug and has no clinical trial or marketing approval status.
|
| Molecular Formula |
13C6H4NA2O9P.XH2O
|
|---|---|
| Related CAS # |
D-Fructose-6-phosphate;643-13-0
|
| Appearance |
White to light yellow oil
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
